Skip to content
10-Q

Quarterly Report

CANNAPHARMARX, INC. CPMD

0001654954-26-005180

← back to feed
Filed
May 20, 2026 12:00 AM ET
Period of report
Restated figures. One or more values in this filing restate previously reported amounts.

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2026 · May 20, 2026 678.5M sh
Shares Diluted Q1 2026 · Mar 31, 2026 669.79M sh
Shares Diluted Q1 2026 · Mar 31, 2025 662.5M sh
Operating Cash Flow Q1 2026 · Mar 31, 2026 −$243.66K
Operating Cash Flow Q1 2026 · Mar 31, 2025 −$601.38K
Cash And Equivalents Q1 2026 · Mar 31, 2026 $633
Cash And Equivalents restated Q1 2026 · Dec 31, 2025 $1.8K
Stockholders Equity Q1 2026 · Mar 31, 2026 −$30.27M
Stockholders Equity Q1 2026 · Dec 31, 2025 −$30.15M
Stockholders Equity Q1 2026 · Mar 31, 2025 −$20.51M
Stockholders Equity Q1 2026 · Dec 31, 2024 −$19.81M
Current Liabilities Q1 2026 · Mar 31, 2026 $31.49M
Current Liabilities Q1 2026 · Dec 31, 2025 $31.59M
Total Liabilities Q1 2026 · Mar 31, 2026 $36.85M
Total Liabilities Q1 2026 · Dec 31, 2025 $37.17M
Current Assets Q1 2026 · Mar 31, 2026 $929.55K
Current Assets Q1 2026 · Dec 31, 2025 $1.31M
Total Assets Q1 2026 · Mar 31, 2026 $6.58M
Total Assets Q1 2026 · Dec 31, 2025 $7.02M
Eps Diluted Q1 2026 · Mar 31, 2026 $0.00
Eps Diluted Q1 2026 · Mar 31, 2025 $0.00
Net Income Q1 2026 · Mar 31, 2026 −$382.02K
Net Income Q1 2026 · Dec 31, 2025 −$10.44M
Net Income Q1 2026 · Mar 31, 2025 −$690.59K
Operating Income Q1 2026 · Mar 31, 2026 −$682.34K
Operating Income restated Q1 2026 · Mar 31, 2025 −$677.59K
Gross Profit Q1 2026 · Mar 31, 2026 −$409.45K
Gross Profit Q1 2026 · Mar 31, 2025 −$502.61K
Cost Of Revenue Q1 2026 · Mar 31, 2026 $1.04M
Cost Of Revenue Q1 2026 · Mar 31, 2025 $837.93K
Revenue Q1 2026 · Mar 31, 2026 $627.46K
Revenue Q1 2026 · Mar 31, 2025 $335.32K